Clinical Trials · NCT00532207

Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Name: Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Teriparatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 50
Start date: Nov 2003
Locations: 1 site, Russia
Primary endpoint: To test the hypothesis that therapy for 12 months with once daily subcutaneous PTH 1-34 (teriparatide; TPTD) 20 micrograms will increase Bone Mineral Density (BMD) at the lumbar spine in postmenopausal women with osteoporosis

View Teriparatide compound reference